Company: AEMD
Filing Date: 2025-08-20
Form Type: S-1
Source: 0001683168-25-006352
Chunk: 11

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-20
Form: S-1
Chunk 11
---
 frameworks for the treatment of severe SARS-CoV-2 infection. While we terminated our
U.S. and India-based COVID-19 studies due to low ICU patient volume and shifting priorities, these programs demonstrated real-world use
of the Hemopurifier in critically ill patients. We maintain an open IDE for viral indications to preserve optionality for future outbreaks
or emergent pathogens.

We have sufficient inventory of
Hemopurifiers to support our ongoing oncology trial in Australia as well as any near-term expansion of that study or potential trial activity
in India. While we have received FDA approval to begin manufacturing at our San Diego facility under our IDE supplement, we are still
awaiting FDA approval of a separate supplement to qualify an additional supplier of a key Hemopurifier component. We continue to work
with the FDA on this process.

Pre-Clinical Exploration of Additional Clinical Uses for the Hemopurifier

The Aethlon R&D laboratory
continues to explore potential new indications for the Hemopurifier. We have published in the peer-reviewed journal Transplant Immunology the ability of the device to remove extracellular vesicles and their microRNA cargo from acellular perfusates of discarded
kidneys that had undergone normothermic machine perfusion.

On May 12, 2025, the results of
our pre-clinical ex vivo study entitled “Ex Vivo Removal of CD41 positive platelet microparticles from Plasma by a Medical Device
containing a Galanthus nivalis agglutinin (GNA) affinity resin” were published in the pre-print vehicle bioRxiv. This manuscript
has been submitted to a peer-reviewed publication for review.

| 3 |

Platelet-derived extracellular
vesicles (PD-EVs) are the most numerous EV population in the body and are released by platelets in response to a variety of stimuli. The
cargo contained within these EVs have been noted to take part in damage to blood vessels, activation of immune cells and spread of tumor
cells. Excessive levels of PD-EVs have been implicated in a myriad of diseases including cancer, lupus, systemic sclerosis, multiple sclerosis,
Alzheimer’s disease, sepsis, acute and Long COVID.

We hypothesized that the Aethlon
Hemopurifier which contains a propriety GNA affinity resin would remove platelet derived EVs from plasma. In this experiment two hundred
milliliters on donated healthy human plasma were circulated over the Aeth